MAXIMILIAN DIEHN

M.D., Ph.D., Assistant Professor, Stanford University School of Medicine

Max Diehn MD, PhD is an Assistant Professor of Radiation Oncology at Stanford University. He has co-appointments in the Stanford Cancer Institute and Institute for Stem Cell Biology and Regenerative Medicine. Dr. Diehn trained at Harvard University and Stanford University and has a background in genomics and stem cell biology. He is also a board certified Radiation Oncologist and specializes in treatment of lung cancer. Dr. Diehn’s research programs spans basic, translational, and clinical studies. He has made significant contributions in number of areas, including in cancer stem cell biology and cancer genomics. His group recently developed a next generation sequencing-based method for detection of circulating tumor DNA called CAPP-Seq. Further development and clinical application of this approach are major ongoing research efforts in his laboratory.

 

Analysis of Circulating Tumor DNA for Personalized Cancer Detection and Monitoring. 

Circulating tumor DNA (ctDNA) represents a promising biomarker for sensitive, specific, and dynamic detection of disease burden in cancer patients. Additionally, ctDNA analysis allows non-invasive access to cancer genomes and therefore can be used for biopsy-free tumor genotyping and detection of resistance mutations. In this presentation I will discusses promises and challenges of using ctDNA as a cancer biomarker, with a focus on technical aspects of ctDNA detection and clinical applications.

Web Analytics